• Like a focused Horizon Therapeutics (the company that developed Tepezza) aiming to develop next-generation treatments for Thyroid Eye Disease.
• An early-stage Regeneron, but specializing its antibody drug development solely on treatments for Thyroid Eye Disease.

• VRDN-001: A humanized monoclonal anti-IGF-1R antibody in clinical trials for the treatment of thyroid eye disease (TED).
• VRDN-002: An IGF-1R antibody currently in Phase 1 clinical trial.
• VRDN-003: A therapeutic antibody targeting IGF-1R for the treatment of thyroid eye disease (TED).

Viridian Therapeutics, Inc. (VRDN) is a clinical-stage biotechnology company focused on the development of treatments for serious diseases. As described in the background, its primary drug candidates (VRDN-001, VRDN-002, and VRDN-003) are currently in various phases of clinical trials.

Due to its stage of development, Viridian Therapeutics does not yet have commercialized products generating revenue from sales. Therefore, the company does not currently have major customers, either other companies or categories of individuals, for its therapeutic products.

Xencor, Inc. (XNCR)

Steve Mahoney, President and Chief Executive Officer

Steve Mahoney is Viridian's President and Chief Executive Officer and a member of the Board of Directors, appointed in October 2023. He brings over two decades of experience in operational, financial, commercial, legal, and transactional roles, with a track record of scaling organizations from founding through commercial stages. Prior to Viridian, he served as Chief Financial and Operating Officer of Magenta Therapeutics. He was also part of the founding team of Kiniksa Pharmaceuticals, where he held the position of President and Chief Operating Officer. Earlier in his career, Mahoney was Chief Commercial Officer of Synageva Biopharma and served as a commercial attorney with Genzyme Corporation and a corporate attorney with Mintz Levin. He currently serves on the board of directors of Vesselon, Inc., a private company.

Seth Harmon, Chief Financial Officer

Seth Harmon was promoted to Chief Financial Officer of Viridian Therapeutics in January 2025, having joined the company in 2023 as Senior Vice President of Finance and Accounting. He possesses 20 years of experience in strategic finance, accounting, and operations. Before joining Viridian, Harmon was the CFO of BioNTech US, where he managed the general and administrative functions for BioNTech SE's U.S. subsidiary and contributed to its growth from 56 to over 500 employees. His previous experience includes finance roles of increasing seniority at Neon Therapeutics and Merrimack Pharmaceuticals. He began his career at Ernst and Young, spending a decade in their audit and assurance practices.

Tom Beetham, Chief Operating Officer

Tom Beetham joined Viridian as Chief Operating Officer in 2023. He has over 25 years of experience in operations, business development, strategy, and legal within the biopharmaceutical industry. Prior to Viridian, Beetham served as Chief Legal Officer of Magenta Therapeutics, Inc. He was also a member of the founding team at Kiniksa Pharmaceuticals, where he held the positions of Executive Vice President, Corporate Development and Operations, and Chief Legal Officer.

Radhika Tripuraneni, M.D., Chief Medical Officer

Dr. Radhika Tripuraneni joined Viridian in 2024 as a consultant and was appointed Chief Medical Officer in 2025. She brings over 25 years of experience in drug development, covering clinical science, medical affairs, and business development functions. Most recently, Dr. Tripuraneni worked as an independent consultant, advising various venture capital firms, investment funds, and biotech companies on strategic clinical development plans and investment diligence.

Tony Casciano, Chief Commercial Officer

Tony Casciano serves as the Chief Commercial Officer at Viridian Therapeutics.

Key Risks to Viridian Therapeutics (VRDN)

Viridian Therapeutics, a biotechnology company focused on developing treatments for serious diseases, primarily Thyroid Eye Disease (TED), faces several key risks as it advances its product pipeline.

1. Clinical Trial and Regulatory Approval Risk: Despite positive Phase 3 data for its lead candidate, veligrotug (VRDN-001), for Thyroid Eye Disease (TED), there remains an inherent risk of regulatory delays or denial of approval by health authorities such as the FDA or EMA. While veligrotug's Biologics License Application (BLA) has been accepted for Priority Review with a PDUFA target action date of June 30, 2026, approval is not guaranteed. Additionally, VRDN-003, another key IGF-1R antibody for TED, is in ongoing Phase 3 pivotal clinical trials, which carry the risk of not meeting endpoints or revealing unexpected safety concerns. Historically, clinical trials have significant attrition rates, with approximately 40% of Phase 3 candidates failing due to inadequate benefit or emerging safety issues.
2. Intense Competition in the Thyroid Eye Disease (TED) Market: The market for TED treatments is highly competitive. Teprotumumab (Tepezza), an anti-IGF-1R monoclonal antibody, is already an FDA-approved and established treatment for TED. Viridian's veligrotug (VRDN-001) targets the same mechanism, placing it in direct competition with an existing market leader. Although Viridian aims to differentiate its therapies through potentially better safety/tolerability profiles, faster onset, or more convenient administration (e.g., subcutaneous VRDN-003), market penetration against an entrenched therapy can be challenging. Furthermore, the TED pipeline includes several other emerging therapies with diverse mechanisms of action, and five Phase 3 programs are reportedly nearing submission, indicating an intensifying competitive landscape.
3. Financial Sustainability and Capital Requirements: As a clinical-stage biopharmaceutical company, Viridian Therapeutics incurs substantial costs for research, development, and commercialization activities. The company has reported a significant accumulated deficit and ongoing net losses. While Viridian holds cash reserves, securing additional financing is often necessary to fund continued operations, clinical trials, and potential commercial launches. This reliance on external capital can expose existing shareholders to the risk of dilution. Delays in clinical trials or regulatory approvals, or challenges in manufacturing and scaling up production, could further escalate expenses and exacerbate financial pressures.

The successful development and commercialization of a highly effective oral treatment for thyroid eye disease (TED) by a competitor, particularly an oral IGF-1R inhibitor. Such a product would offer a significant convenience advantage over Viridian's injectable antibody pipeline (VRDN-001, VRDN-002, VRDN-003), potentially capturing substantial market share and making Viridian's offerings less competitive upon their potential launch.

Viridian Therapeutics (VRDN) is poised for significant future revenue growth over the next 2-3 years, driven primarily by the advancement and commercialization of its pipeline assets, particularly those targeting Thyroid Eye Disease (TED).

Key Drivers of Future Revenue Growth:

1. Commercial Launch of Veligrotug (VRDN-001) for Thyroid Eye Disease (TED): The most immediate and significant driver of revenue growth is the anticipated commercial launch of veligrotug, a humanized monoclonal anti-IGF-1R antibody for TED. The Biologics License Application (BLA) for veligrotug was accepted by the FDA with a PDUFA target action date of June 30, 2026, under Priority Review. Commercial preparations are actively underway for a potential mid-2026 U.S. launch, and the company plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency in Q1 2026. This launch is expected to have a "transformational impact" on the company's revenue.
2. Approval and Launch of Elegrobart (VRDN-003) for Thyroid Eye Disease (TED): Following veligrotug, the approval and subsequent launch of elegrobart (VRDN-003) is another critical revenue driver. Topline Phase 3 results for subcutaneous elegrobart (REVEAL-1 and REVEAL-2 trials) are expected in Q1 2026 and Q2 2026, respectively. Analysts anticipate VRDN-003 could be approved around 2027. Elegrobart is being developed as a potential best-in-class subcutaneous therapy for TED, offering advantages such as a longer half-life and shorter infusion times compared to other treatments, which could capture significant market share.
3. Advancement and Potential Expansion of FcRn Inhibitor Portfolio (VRDN-006 and VRDN-008): Viridian is actively progressing its portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, with the potential to treat multiple autoimmune diseases. VRDN-006 has shown proof-of-concept in Phase 1 trials by achieving IgG reductions, and the company expects to provide development plans in 2026. The Investigational New Drug (IND) for VRDN-008, a bi-specific half-life extended FcRn inhibitor, was submitted in December 2025, with Phase 1 healthy volunteer data anticipated in the second half of 2026. While these programs are in earlier stages, successful advancement could open new markets and therapeutic indications beyond TED, contributing to long-term revenue growth.

Share Issuance

• In October 2025, Viridian Therapeutics completed an underwritten public offering of common stock, generating approximately $289.1 million in gross proceeds, intended for commercial launch activities, research and development, and general corporate purposes.
• In August 2022, the company executed an upsized underwritten public offering with gross proceeds of approximately $270 million from the sale of common stock and Series B preferred stock, with proceeds allocated to clinical development programs and general corporate purposes.
• In September 2021, Viridian Therapeutics closed an underwritten public offering of common stock and Series B preferred stock, yielding approximately $97.7 million in gross proceeds for advancing its VRDN-001 and VRDN-002 programs, preclinical development, and general corporate purposes.

Inbound Investments

• In October 2025, Viridian entered into a royalty financing agreement with DRI Healthcare Acquisitions LP, securing access to up to $300 million, including an upfront payment of $55 million and potential near-term milestones of $115 million.
• In October 2025, the company amended its credit facility with Hercules Capital, Inc., providing access to up to $300.0 million, with $30 million in immediate net proceeds after repaying a prior facility.
• Viridian Therapeutics entered into a collaboration and license agreement with Kissei Pharmaceutical Co., Ltd. for veligrotug and VRDN-003 in Japan, which included a $70 million upfront payment receivable in the fourth quarter of 2025.

Capital Expenditures

• Viridian Therapeutics reported capital expenditures of $0.26 million in 2021, $0.80 million in 2022, $0.90 million in 2023, $0.51 million in 2024, and $0.50 million in 2025.
• The primary focus of these expenditures is implicitly tied to supporting the company's research and development activities and advancing its portfolio of clinical-stage programs.